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The application of rapid and affordable genome sequencing technologies to families with a high 
incidence of hematological malignancies (HMs) provides significant opportunities for understanding the 
genetic causes of these cancers.
1
 In one of the few studies published to date using this approach, Goldin 
et al recently reported that a rare variant (rs2230531) within ITGB2 is associated with genetic 
predisposition to chronic lymphocytic leukemia (CLL).
2
 In this study whole exome sequencing (WES) was 
performed in a discovery set of 20 high-risk CLL families. Analysis proceeded on a ‘per family basis’, to 
identify rare (minor allele frequency (MAF) < 1% in population databases), nonsynonymous variants 
shared in the CLL cases, as well as obligate carriers and non-Hodgkin lymphoma (NHL) cases. In 20 
families, 926 variants were prioritized, of which two were identified in multiple families, rs2230531 in 
ITGB2 and rs201725177 in SWI5.  
 
The integrin gene ITGB2 was selected for re-sequencing in 39 additional small CLL families and 173 
unrelated CLL patients from a clinical cohort. Carriers of the variant were identified in four families and 
three of 173 unrelated CLL patients. In summary, this variant was detected in 6 of 59 CLL families and 3 
CLL cases from a clinical cohort, all with a family history of lymphoid malignancy.
2
  
 
Integrins more broadly are known for their role in cancer,
3
 however mutations in ITGB2 have not 
previously been implicated in CLL. Variation in ITGB2 presents as an interesting biological candidate for 
the genetic susceptibility of CLL. Mutations in ITGB2 have been shown to cause leukocyte adhesion 
deficiency type 1 (OMIM:116920), an autosomal recessive disorder where neutrophil function is 
affected and patients suffer from recurring bacterial and fungal infections.
4
 Across 53 tissues in the GTEx 
RNA-seq expression database, ITGB2 is primarily expressed in blood,
5
 supporting a role for this gene in 
diseases of this tissue type. Additionally, Rotunno et al have previously reported this variant in a WES 
study of familial Hodgkin lymphoma.
6
  
 
Here, we examine the ITGB2 variant rs2230531 in an independent cohort of HMs from the Tasmanian 
Familial Hematological Malignancies Study (TFHMS). Our aim was to follow up the findings of Goldin et 
al in relation to the role of this variant in the genetic predisposition to HMs. The TFHMS cohort, 
previously described in detail
7-9
, is a collection of familial and non-familial HM cases and unaffected 
relatives from Tasmania, the island state of Australia. Using TaqMan genotyping (ThermoFisher 
Scientific, assay ID: C__15852956_10), we genotyped rs2230531 in 71 affected and 228 unaffected first-
degree relatives from 47 families, in addition to 80 non-familial HM cases from the TFHMS cohort 
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(n=379, 48.3% male), together with two Tasmanian population control datasets (n=862), detailed 
further in Table 1. 
 
Table 1. Characteristics of ITGB2 rs2230531 variant carriers  
 
Individual Sex Cohort HM Diagnosis Age
*
 Relationship to closest HM case 
 
LK0016-104 Male TFHMS Unaffected 62 Offspring of parent with DLBCL and 
AML, DNA of parent unavailable 
LK0051-159 Female TFHMS DLBCL 58 NA 
LK0600-005 Female TFHMS Unaffected 71 3 affected siblings, 2 with MM and 1 
with HL, all negative for variant 
LK0800-001 Male TFHMS AML 59 Non-familial 
LK0933-001 Male TFHMS HCL 66 Non-familial 
LK2042-056 Female TFHMS Unaffected 69 Offspring of parent with NHL, DNA 
of parent unavailable 
LK2042-290 Female TFHMS ET 52 NA 
DVA 538 Male TPC Unaffected 69 No known family history of HMs 
DVA 655 Male TPC Unaffected 61 No known family history of HMs 
PCT0-166 Male TPC Unaffected 84 No known family history of HMs 
DVA 1519 Male TPC Unaffected 70 No known family history of HMs 
DVA 1527 Male TPC Unaffected 70 No known family history of HMs 
DVA 1737 Male TPC Unaffected 80 No known family history of HMs 
PCT0-010 Male TCC Unaffected 84 No known family history of HMs 
PCC0-011 Male TCC Unaffected 72 No known family history of HMs 
DVA 88 Male TCC Unaffected 80 No known family history of HMs 
DVA 100 Male TCC Unaffected 82 No known family history of HMs 
PCT0-146 Male TCC Unaffected 77 No known family history of HMs 
DVA 394 Male TCC Unaffected 70 No known family history of HMs 
DVA 1005 Male TCC Unaffected 78 No known family history of HMs 
DVA 1022 Male TCC Unaffected 77 No known family history of HMs 
DVA 1025 Male TCC Unaffected 70 No known family history of HMs 
DVA 1029 Male TCC Unaffected 71 No known family history of HMs 
DVA 1059 Male TCC Unaffected 68 No known family history of HMs 
PC46-002 Male TCC Unaffected 93 No known family history of HMs 
PC65-001 Male TCC Unaffected 82 No known family history of HMs 
 
Abbreviations: HM hematological malignancy, TFHMS Tasmanian Familial Hematological Malignancies 
Study, TPC Tasmanian population controls comprised of 344 male Tasmanian population controls 
undiagnosed for HMs according to Tasmanian Cancer Registry records up to December 2014, TCC 519 
male Tasmanian non-HM cancer cases, DLBCL diffuse large B-cell lymphoma, MM multiple myeloma, HL, 
Hodgkin lymphoma, AML acute myeloid leukemia, HCL hairy cell leukemia, NHL non-Hodgkin lymphoma, 
ET essential thrombocythemia, NA not applicable. 
*
Age = age in years at diagnosis for HM cases and 
current age for non-HM samples.   
 
 
For personal use only.on May 25, 2017. by guest  www.bloodjournal.orgFrom 
 4
 
 
We identified four HM cases as carriers of the rs2230531 variant in the TFHMS cohort. Two HM cases 
carrying rs2230531 had a family history of HMs, and two were non-familial cases. Three unaffected 
relatives of HM cases were also identified as variant carriers. An unaffected relative and a familial HM 
case were identified in the same family, however the two are only distantly related and separated by 12 
meioses (based on genealogical records). We also detected the variant in our Tasmanian population 
non-HM cohorts (TPC and TCC, Table 1) with an overall MAF of 0.011. None of the 25 CLL cases 
screened, or their first-degree relatives were found to carry the variant. Table 1 describes the 
characteristics of the individuals carrying this variant. Supplementary Table S1 details HM subtypes 
included in these analyses. 
 
To appropriately test the enrichment of rs2230531 in HM families compared to population controls, 
there is a need to account for the non-independence of related samples in TFHMS. To do this, we used a 
maximum likelihood estimate (MLE) of the MAF in the TFHMS families, taking into account the pedigree 
structure, using SOLAR.
10
 MLEs were compared across groups using a Wald test (with one degree of 
freedom). As an additional population control group for comparison, allele frequency data were also 
leveraged for rs2230531 from 26,133 samples in the non-Finnish European, non-TCGA (The Cancer 
Genome Atlas) component of the Exome Aggregation Consortium (ExAC), where the MAF is 0.007.
11
 We 
additionally compared the Tasmanian population control cohort alone, and in combination with the 
TFHMS samples as a single Tasmanian group, against the ExAC sample set.  
 
Table 2 shows the results of Wald test MLE comparisons. Overall, rs2230531 was not enriched in HM 
families in comparison to both Tasmanian population controls (P=0.671) and publicly available 
population data from ExAC (P=0.235). Additionally, rs2230531 was not enriched in Tasmanian controls, 
nor all Tasmanian samples together (TFHMS/TPC/TCC) in comparison to the non-TCGA, non-Finnish 
European component of ExAC (P=0.141 and 0.069 respectively). A post-hoc power analysis was 
performed to consider the power within the TFHMS dataset to detect a difference in allele frequencies 
from the observed allele frequency of 0.011 in the 862 Tasmanian controls. The TFHMS dataset (of 
sample size 379) has 80% power to detect an approximate difference of 0.023 in allele frequency; 50% 
for a 0.014 difference; and 25% for a 0.008 difference. The measured difference was only 0.0022923 
suggesting that no biologically significant difference exists between sample groups. 
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 Table 2. Wald test MLE group comparisons for rs2230531 
 
Frequency Comparison chi (1 d.f.) P  
TFHMS vs TPC/TCC 0.163 0.686 
TFHMS vs non-TCGA NFE ExAC 1.408 0.235 
TPC/TCC vs non-TCGA NFE ExAC 2.162 0.141 
Tasmania vs non-TCGA NFE ExAC 3.3 0.069 
 
Non-TCGA NFE ExAC refers to non-Finnish European, non-TCGA 
(The Cancer Genome Atlas) component of the Exome 
Aggregation Consortium (ExAC) with a MAF for rs2230531 = 
0.0073853. TFHM refers to Tasmanian Familial Hematological 
Malignancy Study with a MAF = 0.013436.TPC refers to 
Tasmanian population control and TCC refers to the male 
Tasmanian non-HM cancer case samples with a combined MAF = 
0.0111437.  Across all Tasmanian samples (TFHMS/TPC/TCC) 
MAF=0.01157. 
 
 
These data provide evidence that the ITGB2 variant rs2230531 is not enriched in Tasmanian families 
with HMs in comparison to both Tasmanian and larger international population cohorts. In our cohort, 
we observe the variant in HM cases other than CLL, including both lymphoid and myeloid HMs, the latter 
being a novel observation. This suggests that if this variant does indeed contribute to HM risk (in other 
populations) it may contribute more broadly across HM subtypes and thus may warrant further analysis 
in other familial HM cohorts and HM subtypes. 
 
An alternative interpretation of these data is that rs2230531 is a rare polymorphism, not associated with 
disease and present in the population at large. This may be a feature of the historically stable and 
isolated Tasmanian population. The established founder effect in Tasmania can lead to the observation 
that some rare variants, reported in large publicly available databases, are enriched in the Tasmanian 
population (occur at a slightly higher frequency in the Tasmanian population; unpublished observation). 
In our non-HM Tasmanian samples, rs2230531 has a MAF of 0.011, whereas in 26,133 samples from 
ExAC the MAF is 0.007. This difference, however, is not statistically significant.   
 
Our findings do not necessarily rule out a role for ITGB2 in CLL or HM genetic predisposition. HM is a 
multifactorial disease and mutations in ITGB2 may play but one part in the larger context of HM risk. Our 
study does serve to provide a necessary sequel to the study of Goldin et al as the evaluation of a disease 
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associated variant in multiple cohorts is required to establish a new genetic cause of disease, as outlined 
in guidelines produced by MacArthur et al.
12
 We propose that the current conflicting findings of the 
rs2230531 in familial HMs, together with the biological role of ITGB2 in blood cells creates an a priori 
hypothesis that genetic variation in ITGB2 contributes to HM risk. Further, this finding should encourage 
other researchers in the field to step beyond the single variant and perform gene-based screening of 
ITGB2 to determine whether multiple, rare, deleterious variants contribute to HM risk. 
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